PUBLISHER: DelveInsight | PRODUCT CODE: 1083587
PUBLISHER: DelveInsight | PRODUCT CODE: 1083587
DelveInsight's, "Biliary Tract Cancer (BTC)- Epidemiology Forecast-2032" report delivers an in-depth understanding of the Biliary Tract Cancer (BTC), historical and forecasted epidemiology as well as the Biliary Tract Cancer (BTC) trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Study Period: 2019-2032.
Biliary tract cancers (BTC) constitute epithelial malignancies of the biliary tree and include the following: Gallbladder cancer (GBC) and Cholangiocarcinoma (CCA). CCA is further divided into intra-hepatic CCA, perihilar (Klatskin's tumor), and distal CCA. Gallbladder cancer is a rare disease in which malignant (cancer) cells are found in the tissues of the gallbladder. It originates in the cells of the gallbladder and most are adenocarcinomas, which begin in the gland cells of the gallbladder lining. Cholangiocarcinoma is a type of cancer that develops within the bile duct system, which is a series of small tubes that transport bile fluid from the liver (where it is produced) to the gallbladder (where it is stored).
The signs and symptoms of Biliary Tract Cancer may include pruritus, abdominal pain, malaise, fatigue, jaundice, fever, and more. The majority of BTC cases develops in the absence of identifiable risk factors, as most cases are sporadic and have no identifiable risk factors. However, several conditions have been linked to carcinogenesis which can include primary sclerosing cholangitis, parasitic infections, intrahepatic biliary stones, Caroli's disease, and others.
For a definitive diagnosis, patients usually undergo endoscopic retrograde cholangiopancreatography and several procedures named as cytology, brushing, FISH (fluorescence in situ hybridization)-polisomy, biopsy, ultrasonography, choledochoscopy, cholangioscopy, chromoendoscopy, confocal endoscopy, narrow-band imaging. MRI, CT, endoscopic ultrasonography, or 18FDG PET-CT cannot definitively demonstrate the stricture's neoplastic nature.
Endoscopic ultrasonography-guided fine-needle aspiration demonstrated good diagnostic performance for discriminating benign versus malignant biliary strictures and without apparent risk of tumor seeding linked with the procedure. As for iCCA, the risk of tumor seeding after transperitoneal biopsy of pCCA is based on limited evidence. The role of FISH-polisomy in detecting CCA in patients with PSC has been questioned by a meta-analysis due to its limited sensitivity. Better markers are therefore required for early CCA detection. In this regard, serum CA19-9 levels can be helpful for the detection of CCA. However, the CA19-9 serum level is biased by elevation due to cholangitis and cholestasis and is undetectable in Lewis-antigen-negative patients.
The epidemiology section provides insights about the historical and current Biliary Tract Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Biliary Tract Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total number of Biliary Tract Cancer cases was 37,451 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Biliary Tract Cancer epidemiology [segmented as Total Incident Cases of BTC, Total age-specific cases of BTC, Total stage-specific cases of BTC, Total mutation-specific cases of BTC, and Total treated cases of BTC] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the Biliary Tract Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
To keep up with the current Biliary Tract Cancer patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Biliary Tract Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.